{"id":"W2105167551","doi":"10.1016/s0140-6736(11)61649-8","title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","year":2011,"lang":"en","type":"article","venue":"The Lancet","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":741,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; McGill University; University of British Columbia","funders":"F. Hoffmann-La Roche; IC Design Education Center; Biogen Idec; Biogen","keywords":"Ocrelizumab; Medicine; Placebo; Interferon beta-1a; Multiple sclerosis; Clinical endpoint; Internal medicine; Population; Clinical trial; Immunology; Rituximab; Interferon beta; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003781006,0.002749715,0.005039065,0.0005918401,0.0007659646,0.001402657,0.001109887,0.003747343,0.004231222],"category_scores_gemma":[0.003806085,0.0009086529,0.003444968,0.0006700605,0.001491686,0.001597334,0.0006346962,0.003227598,0.0007712336],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001102723,"about_ca_system_score_gemma":0.001414823,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001768013,"about_ca_topic_score_gemma":0.003151405,"domain_scores_codex":[0.9984347,0.0008178146,0.0001265242,0.0002563274,0.0001268279,0.0002377433],"domain_scores_gemma":[0.9984034,0.000601246,0.0003507334,0.0001485952,0.0001213627,0.0003746335],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9849438,0.001455131,0.0004393139,0.001234528,0.001447974,0.0000502476,0.000066077,0.0001362476,0.001340773,0.00007489813,0.0006223753,0.008188615],"study_design_scores_gemma":[0.9867856,0.01139651,0.0007456053,0.00003802351,0.0004892107,0.00002631251,0.00001652765,0.00006236108,0.00009277261,0.00005597794,0.0002827496,0.000008347552],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9638557,0.02578107,0.0007555262,0.001590731,0.001297667,0.003344255,0.001297434,0.0001105302,0.001967045],"genre_scores_gemma":[0.9749519,0.009782521,0.002554868,0.002627307,0.001027633,0.004320039,0.001454579,0.00003479402,0.003246402],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005039065,"threshold_uncertainty_score":0.01999611,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1512711031892404,"score_gpt":0.3369648857764854,"score_spread":0.185693782587245,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}